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Background: Bixalomer (BXL) was developed to improve gastrointestinal symptoms and reduce constipation,
relative to sevelamer hydrochloride, in hemodialysis patients. We prospectively evaluated the safety and
effectiveness of switching maintenance dialysis patients from sevelamer hydrochloride to BXL.
Methods: Twenty-eight patients were switched from sevelamer hydrochloride to BXL (1:1 dose) from July to
October 2012, whereas 84 randomly selected patients not treated with sevelamer hydrochloride were enrolled as a
control group. The primary endpoint was improvement of gastrointestinal symptoms; secondary endpoints
included improvement in metabolic acidosis, changes in blood biochemistry, and safety 12 weeks after the switch.
We also surveyed patient satisfaction with switching to BXL 12 weeks after the switch.
Results: Before switching, symptoms of epigastric fullness were significantly worse in the switch than in the control
group. Twelve weeks after the switch, reflux, epigastric fullness, and constipation had improved significantly in the
switch group. Other factors, including stomach ache, diarrhea, and form of stool, did not change significantly. Blood
gas analysis showed that metabolic acidosis was significantly improved by switching. Four patients (14%)
experienced grade 1 adverse events, all of which improved immediately after stopping BXL. Major adverse events
were diarrhea and abdominal discomfort. Mean satisfaction score was 3.1 ± 0.7, with 64% of patients reporting they
were “neither satisfied nor dissatisfied” after switching.
Conclusions: A switch from sevelamer hydrochloride to BXL improved symptoms of reflux, epigastric fullness,
constipation, and metabolic acidosis in hemodialysis patients.
Trial registration: The study was registered as Clinical trial: (UMIN000011150).
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Hyperphosphatemia is highly prevalent in patients
undergoing hemodialysis and is one of the most import-
ant risk factors for cardiovascular disease and mortality
in these patients [1]. A high serum level of phosphorous
promotes calcium phosphate calcifications. Calcification
of the myocardium or peripheral artery significantly
increases the risk of cardiovascular disease in dialysis
patients [2]. In most patients, dietary restrictions and
three times-weekly hemodialysis sessions are insufficient
to reduce phosphate levels to the treatment goals of the
National Kidney Foundation (NKF K/DOQI) [3]. Thus,
phosphate-binding agents are necessary for dialysis
patients with hyperphosphatemia.
Currently available therapeutic agents for hyper-
phosphatemia include calcium-containing phosphate
binders (calcium carbonate and calcium acetate), lan-
thanum carbonate, and ion-exchange resins. Sevelamer
hydrochloride is an ion-exchange resin of non-absorbable
hydrogel that reduces serum phosphorus levels. The disad-
vantages of this agent include gastrointestinal symptoms
due to high pill burden [4] and metabolic acidosis [5].
Gastrointestinal adverse events occur frequently in Japanese
dialysis patients, preventing their long-term treatment with
sevelamer hydrochloride [6]. Metabolic acidosis not only
has adverse effects on bone, and on protein and amino-acid
metabolism, but reduces overall survival [7]. Metabolic
acidosis caused by sevelamer hydrochloride may be
reduced by the use of sevelamer carbonate, but the latter

















Figure 1 Study design and disposition of subjects. A total of 112 patie
blood biochemistry and blood gas were assessed at 0 (baseline), 4, 8, and
questionnaires were administered at 0 and 12 weeks, and blood biochemis
performed in the control group.Bixalomer (BXL) is a non-calcium, metal-free amine-
functional polymer that reduces serum phosphorus
levels by binding to phosphate in the gastrointestinal
tract and inhibiting its absorption. A phase III trial of
hemodialysis patients in Japan showed the clinical efficacy
of BXL in reducing serum phosphorus levels, as well as its
preferable long-term safety profile [8]. BXL was therefore
approved in June 2012 to treat hyperphosphatemia in
Japan. The lower rates of gastrointestinal symptoms and
metabolic acidosis observed with BXL relative to sevelamer
hydrochloride have been attributed to its lower coefficient
of expansion and the absence of chloride [9].
We prospectively investigated the effectiveness and
safety of a 1:1 dose switch from sevelamer hydrochloride
to BXL in stable hemodialysis patients, including the
effects of the switch on gastrointestinal symptoms,




This was a single-center, open-label, non-randomized
controlled study performed in hemodialysis patients
with hyperphosphatemia. This study was performed in
accordance with the ethical standards of the Declaration of
Helsinki and was approved by the institutional ethics com-
mittee of the Oyokyo Kidney Research Institute, Hirosaki,
Japan. All patients provided written informed consent.
The study design is illustrated in Figure 1. A total of
530 patients on maintenance hemodialysis were treatedSwitch to 
bixalomer 
Questionnaire and blood biochemical test 
at 0, 4, 8, 12 weeks 
Questionnaire at 0, 12 weeks  
Blood biochemical test at 0, 4, 8, 12 weeks 
Satisfaction 
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nts were enrolled in this study. Questionnaires were administered and
12 weeks after the switch in the switch group. In the control group,
try assessed at 0, 4, 8, and 12 weeks. Blood gas analysis was not
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hyperphosphatemia who were taking oral sevelamer
hydrochloride. Of these, 28 provided consent to switch
from sevelamer hydrochloride to BXL (1:1 dose) from
July to October 2012 (switch group). The control group
consisted of 84 stable hemodialysis patients not taking
sevelamer hydrochloride, randomly selected by random
number tables using patient identification number. Patients
were included if they (1) were aged 20 to 80 years; (2) were
stable on hemodialysis sessions started at least 1 year
before study entry; (3) provided written informed
consent to participate; (4) had not changed their regimen
of phosphate-lowering drugs, cinacalcet hydrochloride
(if used), and other medications that could affect
serum phosphorus levels for at least 28 days before
study entry; (5) had not changed their dialysis regimens
for at least 28 days before study entry; (6) had not changed
other factors, including dietary therapy and concomitant
drugs, during the study period; and (7) were in good
general health, with an Eastern Cooperative Oncology
Group Performance Status (ECOG-PS) grade of 0 or 1 [10].
Patients were excluded if they (1) had a history of gastro-
intestinal surgery (excluding polypectomy), dysphagia, ileus,
gastrointestinal bleeding, severe persistent constipation or
diarrhea, or had received parathyroid intervention within
3 months of study entry; (2) showed unstable control of
serum phosphorus and calcium levels; or (3) were in poor
general health, or had a major concomitant malignant
disease or other medical condition likely to result in death
within 6 months of study entry.Assessments
The primary endpoint was improvement of gastrointestinal
symptoms. Secondary endpoints included improvements in
metabolic acidosis, changes in blood biochemistry, and
safety.
Gastrointestinal symptoms and form of stool were
assessed at baseline (0) and 4, 8, and 12 weeks after
switching in the switch group, and at 0 and 12 weeks
in the control group. Hemoglobin, serum albumin,
phosphorus, and calcium levels and metabolic acidosis
were measured at 0, 4, 8, and 12 weeks in both groups.
Gastrointestinal symptoms were assessed using the Izumo
scale [11] and stool form was evaluated using the Bristol
stool scale [12,13]. The Izumo scale is a self-reported
questionnaire designed to determine the quality of life
of patients with upper and/or lower abdominal symptoms.
The questionnaire consists of 15 questions in five domains:
reflux, stomach ache, epigastric fullness, constipation, and
diarrhea. Each question is rated on a 6-point scale, from 0
to 5, with higher values indicating more severe symptoms.
The scores of questions within a domain can be added to
determine domain-specific scores.The Bristol stool scale is designed to classify the form
of human feces into seven categories: separate hard lumps,
like nuts, which are hard to pass (Type 1); sausage-
shaped, but lumpy (Type 2); like a sausage but with cracks
on its surface (Type 3); like a sausage or snake, smooth
and soft (Type 4); soft blobs with clear-cut edges, easily
passed (Type 5); fluffy pieces with ragged edges, and
mushy (Type 6); and watery, no solid pieces (Type 7).
Adverse events were evaluated according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE),
version 4.0 [14].
Satisfaction with BXL compared with sevelamer
12 weeks after the switch was assessed in the switch
group using a 5-level rating questionnaire.
Statistical analysis
Symptom scores were compared before and 3 months
after switching in the switch group using paired t tests,
and between the switch and control groups using
Mann–Whitney U tests. Changes of metabolic acidosis
and blood biochemistry parameters were compared before
and after switching in the switch group using paired t
tests. All statistical analyses were performed using
GraphPad Prism version 5.03 (GraphPad software,




The background of the included patients is shown in
Table 1. All were receiving hemodialysis. Overall mean
age was 60.2 ± 10.8 years, 57 ± 12 years in the switch
group and 61 ± 10 years in the control group, and overall
mean duration of dialysis was 11.6 ± 6.5 years. Most
patients (83%) had used other anti-phosphorus agents,
including calcium-containing phosphate binders and
lanthanum carbonate (Table 1). There were no significant
between group differences in patient demographic and
clinical characteristics, except for administration of
potassium absorbent (P = 0.047), and components of
other anti-phosphorus agents (P = 0.001). The mean
dosage of sevelamer hydrochloride before the switch
was 2054 ± 780 mg/day.
Izumo scale and bristol stool scale
Gastrointestinal symptom analysis was performed after
excluding the four patients who stopped taking BXL
soon after switching. All symptom scores are summarized
in Table 2. Total gastrointestinal symptom scores in the
switch group 3 months after switching were similar to
those in the control group. However, when we compared
gastrointestinal symptom scores in the switch group
before and 3 months after switching, we observed
significant improvements.
Table 1 Demographic profile of the subjects
All Switch group Ctrl group P value
n 112 28 84
Age (Y) 60.2 ± 10.8 57.3 ± 12.0 61.2 ± 10.3 0.134
Gender (M/F) 55/57 14/14 41/43 0.913
Dialysis vintage (Y) 11.6 ± 6.5 12.1 ± 6.4 11.4 ± 6.6 0.604
Use of Psychotropic agents 39(35%) 12(43%) 27(32%) 0.594
Use of vitamin D analogues 46(41%) 14(50%) 32(38%) 0.267
Use of other phosphorus agents 93(83%) 24(86%) 69(82%) 0.660
Precipitated calcium carbonate 58(51%) 21(75%) 36(43%) 0.001
Lanthanum carbonate hydrate 12(11%) 3(11%) 9(11%)
Precipitated calcium carbonate plus Lanthanum carbonate hydrate 24(21%) 0(0%) 24(28%)
No agents 19(17%) 4(14%) 15(18%)
Use of Potassium absorbent 47(42%) 17(61%) 30(36%) 0.047
Use of laxative 31(28%) 5(18%) 26(31%) 0.179
Cardiovascular disease 36(32%) 9(32%) 27(32%) 1.000
Diabetes mellitus 28(25%) 8(29%) 20(24%) 0.614
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worse (P = 0.028) in the switch group before the switch
than in the control group, but other symptoms did not
differ significantly in the two groups. Twelve weeks after
the switch, symptoms of reflux, epigastric fullness, and
constipation had improved significantly in the switch
group, resulting in no significant between-group differ-
ence in epigastric fullness. Other factors, including
stomach ache, diarrhea, and the Bristol stool scale, did
not differ significantly in the two groups (Table 2). BloodTable 2 Changes in gastrointestinal symptoms, Bristol stool s
sevelamer hydrochloride to bixalomer and in control patient
Switch group, n = 24 Ctrl grou
Before 3 months P value* Before
[Questionnaires]
Reflux 2.0 ± 2.9 1.3 ± 2.4 0.044 1.3 ± 2.5
Stomach ache 1.1 ± 1.6 1.1 ± 2.0 1.000 0.8 ± 2.0
Epigastric fullness 3.0 ± 3.2 1.9 ± 3.2 0.069 1.5 ± 2.1
Constipation 3.0 ± 2.9 1.5 ± 2.0 0.004 2.1 ± 2.4
Diarrhea 2.2 ± 2.4 1.7 ± 2.1 0.274 2.1 ± 2.3
Total score 11.3 ± 10.5 7.5 ± 10.1 0.011 7.9 ± 9.4
Bristol scale 4.1 ± 1.0 4.0 ± 1.0 0.704 4.4 ± 1.1
[Blood gas analysis]
pH 7.36 ± 0.04 7.39 ± 0.04 0.004
HCO3- 19.7 ± 2.3 21.3 ± 3.2 0.028
BE (vt) −5.0 ± 2.5 −3.3 ± 3.1 0.012
Anion Gap 19.6 ± 3.3 15.8 ± 3.1 0.000
*, paired t test, **, Mann–Whitney U test.gas analysis showed that metabolic acidosis, including
pH (Figure 2A), HCO3- concentrations (Figure 2B),
base excess (Figure 2C), and anion gap (Figure 2D),
were significantly improved in the switch group.
Blood biochemical analysis
Before the switch, serum phosphorus level (Figure 3C)
and calcium × phosphorus product (Figure 3E) were
significantly higher in the switch than in the control
group. After the switch, the calcium × phosphoruscale, and metabolic acidosis in patients switched from
s
p, n = 84 Swich vs. Ctrl Swich vs. Ctrl
3 months P value* P value** (Before) P value** (3 months)
0.9 ± 1.8 0.117 0.067 0.193
0.6 ± 2.0 0.422 0.057 0.122
1.3 ± 2.4 0.417 0.028 0.554
1.5 ± 2.0 0.073 0.143 0.855
1.4 ± 2.2 0.042 0.685 0.414
5.7 ± 8.2 0.117 0.062 0.814
4.1 ± 1.1 0.083 0.209 0.594






































*, P<0.05, **, P<0.01
A B
C D
Figure 2 Changes of metabolic acidosis. All parameters of metabolic acidosis (A: pH, B: HCO3
- , C: base excess, D: anion gap) improved
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Figure 3 Changes of blood biochemistry parameters. Changes of blood biochemistry parameters in hemoglobin (A), serum albumin
(B), serum phosphorus (C), correlated calcium (D) and calcium × phosphorus product (E). Serum phosphorus levels were significantly higher
in the switch group before than after switching. No blood biochemical parameter changed significantly. (#, P < 0.05, paired t tests, compared
with the control group).







































Figure 4 Satisfaction survey for bixalomer. Satisfaction with
BXL was assessed by a 5-level rating, including “very dissatisfied
(score 1)”, “somewhat dissatisfied (score 2)”, “neither satisfied nor
dissatisfied (score 3)”, “somewhat satisfied (score 4)”, and “very
satisfied (score 5)”. The most frequent answer after switching (64%)
was “neither satisfied nor dissatisfied”, with only seven patients (25%)
reporting being “somewhat satisfied” after the switch. The mean
score was 3.1 ± 0.7.
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There were no significant changes in hemoglobin
(Figure 3A), serum albumin (Figure 3B), and calcium
(Figure 3D) levels before and after the switch.
Adverse events
Four patients in the switch group (14%) experienced
CTCAE grade 1 adverse events, all of which improved
immediately after stopping BXL treatment. The major
adverse events were diarrhea (3.5%) and abdominal
discomfort (3.5%). Details of adverse events are shown
in Table 3.
Satisfaction surveys
Satisfaction with BXL was assessed by a 5-level rating,
including “very dissatisfied”, “somewhat dissatisfied”,
“neither satisfied nor dissatisfied”, “somewhat satisfied”,
and “very satisfied” in all 28 switched patients. The mean
satisfaction score was 3.1 ± 0.7, with most patients (64%)
reporting that they were “neither satisfied nor dissatisfied”
after the switch (Figure 4).
Discussion
We have prospectively investigated the effectiveness and
safety of a 1:1 dose switch from sevelamer hydrochloride
to BXL in stable hemodialysis patients. We observed no
significant difference in total gastrointestinal symptom
score 3 months after switching in the switch compared
with the control group. However, total gastrointestinal
symptom scores in the switch group were improved
3 months after switching compared with before switching.
We found that switching resulted in significant improve-
ments in the Izumo scale, including reflux, epigastric full-
ness, constipation, and total score, suggesting that BXL
may be better tolerated than sevelamer hydrochloride and
may be an option for hemodialysis patients intolerant to
sevelamer hydrochloride. To our knowledge, this is the first
report showing the effects of switching from sevelamer
hydrochloride to BXL.Table 3 Adverse events and grade after switching
Discontinuations patients
n 4 (14%)
Age (Y) 58 ± 11
Gender (M/F) 2 / 2
Dialysis vintage (Y) 17 ± 20
Administration periods (Day) 19 ± 20 (range: 1 – 45)
Reasons of discontinuations No. of cases (%)
Diarrhea (Grade 1) 2 (3.5%)
Abdominal discomfort (Grade 1) 2 (3.5%)
Constipation (Grade 1) 1 (1.8%)
Nausea (Grade 1) 1 (1.8%)A recent phase III trial comparing gastrointestinal
symptoms in patients treated with BXL and sevelamer
hydrochloride found that a significantly lower percentage
of BXL patients experienced gastrointestinal symptoms
[29% (16/55) vs. 47% (26/55), P = 0.0497] [15]. In addition,
abdominal fullness was significantly less common in the
BXL group (2% vs. 13%, P = 0.023). These results suggest
that BXL may give rise to milder and fewer GI symptoms
than sevelamer hydrochloride.
In contrast, a satisfaction survey showed that 64% of
patients answered “neither satisfied nor dissatisfied” after
the switch to BXL, with only seven (25%) reporting they
were “somewhat satisfied”. These contradictory results
may suggest that the reductions in gastrointestinal
symptoms after switching may be limited. Because
86% of switched patients had previously used other
phosphorus absorbing agents or other agents that induce
gastrointestinal symptoms, any improvement in gastro-
intestinal symptoms did not have sufficient statistical power
for clinical significance. Additional studies are needed to
clarify this issue.
We observed that serum phosphorus concentrations
did not change significantly after switching. Recent trials
testing the efficacy of BXL for hyperphosphatemia found
that it was non-inferior to sevelamer hydrochloride,
suggesting that these two agents have similar effects on
hyperphosphatemia [8,16].
As expected, improvements in parameters of metabolic
acidosis were observed after switching. Similar outcomes
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from sevelamer hydrochloride to lanthanum carbonate,
with significant increases in HCO3
- concentrations [17].
Additional studies are needed to address the long-term
benefits of BXL in patients with metabolic acidosis.
The safety profiles of BXL were similar to those previously
described [16]. BXL has shown long-term safety and efficacy
in Japanese hemodialysis patients, with reasons for discon-
tinuation including gastrointestinal disorders such as consti-
pation and diarrhea. In this study, the major adverse events
were CTCAE grade 1 diarrhea and abdominal discomfort.
Although the grade of gastrointestinal adverse events was
usually mild, these events occurred after switching
from sevelamer hydrochloride, indicating the importance
of monitoring hemodialysis patients, even those on BXL,
for gastrointestinal adverse events.
This study had several limitations, including the small
number of patients, the inclusion of patients within a
single institute, and the non-randomized design. It is
therefore difficult to control for selection bias and
patient backgrounds. Randomized trials, involving lar-
ger numbers of patients from multiple institutions,
are therefore necessary to assess the possible benefits
of BXL.
Conclusions
The results of this study demonstrated that gastrointes-
tinal symptoms improved after switching to BXL, and
that symptoms of epigastric fullness 3 months after
switching were identical to those of the control group.
BXL was well tolerated and may provide a new option in
the treatment of hyperphosphatemia in patients under-
going hemodialysis.
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